The FDA on February 11, 2025, approved GOMEKLI®, a kinase inhibitor, for adult and pediatric patients 2 years of age and older with NeuroFibromatosis type 1 (NF1) who have symptomatic Plexiform Neurofibromas (PN) not amenable to complete resection. GOMEKLI® is a product of SpringWorks Therapeutics, Inc.
Bottom Ad
Advertisement
Subscribe
